Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adre
April 22, 2026 4:05 PM EDTApproximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologicrange glucocorticoid dosing at two years75% of patients originally taking dexamethasone transitioned off this treatment, enabling a more physiologic glucocorticoid regimen without compromising androgen controlFindings reinforce durable efficacy and a favorable longterm safety profile in largest interventional trial to date conducted in classic congenital adrenal hyperplasia
SAN DIEGO, April 22, 2026 /PRNewswire/ --... More
